(RTTNews) - Deciphera Pharmaceuticals, Inc. (DCPH), a developer of medicines to improve the lives of cancer patients, on Friday said its INTRIGUE Phase 3 clinical study of QINLOCK in patients with gastrointestinal stromal tumor or GIST previously treated with imatinib has failed to meet the primary endpoint of improved progression-free survival or PFS compared with the standard of care sunitinib.
The study did not achieve the primary efficacy endpoint of progression-free survival (PFS) as determined by independent radiologic review using modified Response Evaluation Criteria in Solid Tumors (RECIST).
The INTRIGUE Phase 3 clinical study is a randomized, global, multicenter, open-label study to evaluate the efficacy and safety of QINLOCK compared to sunitinib in patients with GIST previously treated with imatinib.
In the study, 453 patients were randomized 1:1 to either QINLOCK 150 mg once daily or sunitinib 50 mg once daily for four weeks followed by two weeks without sunitinib.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
